Anavex Reports Predicted Clinical Effect for ANAVEX 2-73 in Computer Simulation Model of Alzheimer’s Disease November 18, 2013
Chronic treatment with the tetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic cholinergic and sigma-1 ligand, alleviates pathology in Tg2576 mice, a transgenic Alzheimer’s disease model. November 11, 2013
Blockade of Tau Hyperphosphorylation and Ab1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and r1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease. November 11, 2013
Anavex Reports ANAVEX 2-73 Blocks Tau and Amyloid-Beta Proteins in a Preclinical Model of Alzheimer’s Disease November 4, 2013
Anavex to Present Data for ANAVEX 2-73 at Society for Neuroscience 2013 Annual Meeting October 29, 2013
Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73 for Alzheimer’s Disease October 22, 2013
Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York September 3, 2013
Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York September 3, 2013
